Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial
    Rana, Ritika
    Cockwell, Paul
    Drayson, Mark
    Cook, Mark
    Pratt, Guy
    Cairns, David A.
    Pawlyn, Charlotte
    Jackson, Graham
    Davies, Faith
    Morgan, Gareth
    Pinney, Jennifer Helen
    BLOOD ADVANCES, 2020, 4 (22) : 5836 - 5845
  • [42] Clinical and Laboratory Factors Associated With Renal Replacement Therapy in Patients With Newly Diagnosed Multiple Myeloma
    Fuentes-Lacouture, Maria
    Lara Orduz, Juan
    Figueroa Emiliani, Jair
    Huerfano, Manuel
    Buitrago, Daniel
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S13 - S14
  • [43] Reversibility of Renal Insufficiency in Patients with Newly Diagnosed Multiple Myeloma and the Role of different induction Regimens
    Bao, Li
    Lu, Jin
    Huang, Xiaojun
    BLOOD, 2014, 124 (21)
  • [44] EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS
    Chen, W.
    Lu, J.
    Hou, J.
    HAEMATOLOGICA, 2013, 98 : 340 - 341
  • [45] Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
    Grzasko, Norbert
    Morawska, Marta
    Hus, Marek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (04): : 187 - 198
  • [46] Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
    Hsu, Pei
    Lin, Ting-Wei
    Gau, Jyh-Pyng
    Yu, Yuan-Bin
    Hsiao, Liang-Tsai
    Tzeng, Cheng-Hwai
    Chen, Po-Min
    Chiou, Tzeon-Jye
    Liu, Jin-Hwang
    Liu, Yao-Chung
    Liu, Chia-Jen
    MEDICINE, 2015, 94 (50)
  • [47] Risk of Early Mortality in Patients with Newly Diagnosed Multiple Myeloma
    Liu, Chia-Jen
    Hsu, Pei
    Lin, Ting-Wei
    Gau, Jyh-Pyng
    Hsiao, Liang-Tsai
    Tzeng, Cheng-Hwai
    Chen, Po-Min
    Yu, Yuan-Bin
    Chiou, Tzeon-Jye
    Liu, Yao-Chung
    Liu, Jing-Hwang
    BLOOD, 2015, 126 (23)
  • [48] Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study
    Wei, Wei
    Shi, Haotian
    Chen, Haimin
    Chen, Xiaoling
    Peng, Rong
    Yu, Wenjun
    Wu, Lixia
    Zhou, Nian
    Zhao, Wenhao
    Xu, Weiwei
    Zhou, Yan
    Yu, Jingjing
    Wei, Daolin
    Zhou, Fan
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [49] Favorable Kidney Recovery by Extracorporeal Light Chain Removal and Anti-Myeloma Treatments in Patients with Newly Diagnosed Multiple Myeloma and Acute Renal Failure
    Silvestrini, Giorgio
    Tatangelo, Paola
    Scaramucci, Laura
    Sfara, Germana
    Bondanini, Francesco
    Niscola, Pasquale
    de Fabritiis, Paolo
    Palumbo, Roberto
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2020, 31 (06) : 1445 - 1447
  • [50] Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
    Zhou, Huixing
    Chang, Long
    Jia, Jing
    Ma, Jie
    Xue, Hua
    Li, Hao
    Huang, Wenrong
    Zhou, Hebing
    Sun, Jingnan
    Su, Liping
    Ma, Yanping
    Huang Hongming
    Jing, Hongmei
    Li, Zhenling
    Ma, Guangyu
    Su, Guohong
    Zhou, Jihao
    Chen, Biyun
    Bao, Li
    Zhang, Zhihua
    BLOOD, 2023, 142